Trials / Withdrawn
WithdrawnNCT05675800
Psilocybin for Major Depressive Disorder
Psilocybin for the Treatment of Major Depressive Disorder
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to assess the effectiveness of psilocybin for the treatment of Major Depressive Disorder and potential therapeutic mechanisms. Enrolled participants will receive a single active dose of psilocybin, or a dose considered high enough to treat depression, administered orally with accompanying psychological support.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Psilocybin | Psilocybin administered with psychological support |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2025-01-01
- Completion
- 2025-03-31
- First posted
- 2023-01-09
- Last updated
- 2024-07-25
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05675800. Inclusion in this directory is not an endorsement.